## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.7% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.39)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Abbott wins FDA clearance, CE mark for Amplatzer Piccolo delivery system**
- Source: MassDevice | 20251218T141628 | Bullish | Relevance: 100%
- Abbott has received both FDA clearance and CE mark for its Amplatzer Piccolo delivery system, designed to treat premature babies with a hole in the heart (PDA). This new system optimizes implantation procedures for the Amplatzer Piccolo Occluder, the worldâ€™s smallest heart device for such infants, simplifying the process and potentially reducing risks for this vulnerable patient population. The system aims to enhance the precision and ease of PDA closure procedures, building on Abbott's commitment to advancing pediatric heart therapies.

**2. New device helps doctors close heart holes in the tiniest preemies**
- Source: Stock Titan | 20251218T140211 | Somewhat-Bullish | Relevance: 100%
- Abbott has received FDA clearance and CE Mark for its Amplatzer Piccolo Delivery System, designed to work with the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA) in premature infants, some weighing as little as two pounds. This new system simplifies the procedure by using a single catheter and improves the precision of device placement, reducing adverse events for this vulnerable patient population. The Amplatzer Piccolo Occluder, which is smaller than a pea, was initially approved in 2019 and remains the only minimally invasive transcatheter treatment for PDA in premature infants.

**3. Peak Financial Advisors LLC Takes Position in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251218T132411 | Bullish | Relevance: 100%
- Peak Financial Advisors LLC has acquired a new stake in Abbott Laboratories (NYSE:ABT) during the third quarter, purchasing 19,074 shares valued at approximately $2.555 million. This makes Abbott Laboratories the firm's 21st largest holding, with institutional investors collectively owning about 75.18% of the stock. Abbott recently reported Q3 EPS of $1.30 and revenue of $11.37 billion, and increased its quarterly dividend to $0.63, yielding approximately 2.0%.

**4. Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025?**
- Source: Simply Wall Street | 20251217T230917 | Somewhat-Bearish | Relevance: 100%
- Abbott Laboratories (ABT) is currently trading around $126 a share, with recent momentum driven by its medical devices and diagnostics portfolio. While a Discounted Cash Flow (DCF) analysis suggests the stock is 72.7% overvalued, its Price-to-Earnings (PE) ratio of 15.8x is significantly below the Medical Equipment industry average, indicating it might be undervalued based on earnings. Simply Wall St's proprietary Fair Ratio for Abbott is 25.6x, further supporting an "undervalued" assessment on an earnings basis.

**5. Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025?**
- Source: Simply Wall Street | 20251217T224303 | Neutral | Relevance: 100%
- Abbott Laboratories (NYSE: ABT) has seen recent stock momentum, with a 15.3% return over the last year. While a Discounted Cash Flow (DCF) analysis suggests it might be overvalued by 72.7% at its current share price of $126, its Price-to-Earnings (PE) ratio of 15.8x is significantly below the industry average, indicating it could be undervalued based on earnings. The article also introduces "Narratives" as a way for investors to create dynamic valuations based on different future outlooks for the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.3B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.1 |
| Current P/E | 24.3 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.0% to -0.7% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.7pp (needs >4.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 48. Elevated volume (1.3x 20MA), institutional activity likely. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.72% (CS: 42) | Neutral |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 0.963x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.43
- **Stop Loss:** $120.39 (4.0% risk)
- **Target:** $130.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $29,852.34
- **Portfolio %:** 29.85%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*